The Big Story

FDA commissioner promises to investigate mifepristone

Food and Drug Administration (FDA) head Marty Makary vowed to review the abortion drug mifepristone after previously saying he had no plans to take action on the drug.

© Greg Nash, The Hill

“As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of an early pregnancy,” Makary wrote in a letter to Sen. Josh Hawley (R-Mo.).

“As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with professional career scientists at the Agency who review this data.”

Hawley has repeatedly tried to pressure the Trump administration into reviewing mifepristone’s safety. In April, the senator urged Makary to review new

See Full Page